Attention Deficit Hyperactivity Disorder (ADHD) medication shortage
Attention deficit hyperactivity disorder (ADHD) medication shortages guidelines November 2024
- Available medicines to treat ADHD: Prescribing available medicines to treat ADHD – SPS - Specialist Pharmacy Service – The first stop for professional medicines advice
- Practical advice to adjusting the clinical management plan for patients affected by the supply disruption of ADHD medicine: Supporting system response to the ADHD medicine shortage
- Prescribing and switching between methylphenidate products:
In discussion with the patient, prescribers can make adjustments to certain methylphenidate brands in short supply, without the need for additional specialist advice. This may be by making a short-term switch to an alternative bio-equivalent brand or formulation, or generic prescription for a methylphenidate modified-release product. Prescribers should revert to normal brand prescribing during periods of normal supply.
Resources to help with switching between methylphenidate products:
· Choice and medication ADHD medication handy facts sheet: A comparison of stimulants to help treat the symptoms of ADHD: handyfactsheetadhdformsuk.pdf
Equivalent MR tablets
The following MR methylphenidate tablets are considered bioequivalent to one another. Generic prescribing could be undertaken and products switched between using the same dose and quantity were that to be necessary:
o Concerta XL
o Affenid XL tablets
o Delmosart tablets
o Matoride XL tablets
o Xaggitin XL tablets
o Xenidate XL tablets
Equivalent MR capsules
The following MR methylphenidate capsules are considered bioequivalent to one another. Generic prescribing could be undertaken and products switched between using the same dose and quantity were that to be necessary:
o Metyrol XL
o Meflynate XL
o Ritalin XL
Note, however, that whilst switches from or to Medikinet XL capsules are also possible, these should be undertaken with particular care since this product is not completely bioequivalent with the other three.
Do not switch Equasym XL capsules
o No other MR products are bioequivalent to Equasym XL capsules and these should not be switched to or prescribed generically.
Do not switch from Methylphenidate MR tablets to MR capsules as they aren’t bioequivalent. Switching from Methyphenidate MR tablets to a bioequivalent dose of MR capsules will require lowering the dose by about 1/3. So 36 mg of Methylphenidate MR tablets equals roughly 20 mg of Methylphenidate MR capsules.